OncLive TV

Peter Martin, MD, discusses the frontline treatment landscape of mantle cell lymphoma.

Srdan Verstovsek, MD, PhD, discusses research efforts being made with CPI-0610 in the treatment of patients with myelofibrosis.

Luciano J. Costa, MD, PhD, discusses the design of a phase 1 first-in-human study with CC-93269 in relapsed/refractory multiple myeloma.

Arnulf Stenzl, MD, discusses the safety profile of enzalutamide in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.

Daniel H. Ahn, DO, discusses left- versus right-sided tumors in colorectal cancer.

Dimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

Nathan Pennell, MD, PhD, discusses challenges with next-generation sequencing in lung cancer.

Oliver Sartor, MD, discusses the significance of the REASSURE trial in patients with metastatic castration-resistant prostate cancer.

Naval G. Daver, MD, discusses updated findings on the combination of the investigational CD47-directed antibody magrolimab and azacitidine in myelodysplastic syndrome.

Charles M. Rudin, MD, PhD, discusses the design of the phase 3 KEYNOTE-604 trial in extensive-stage small cell lung cancer.

Balazs Halmos, MD, MS, discusses the importance of identifying biomarkers in advanced non–small cell lung cancer.

Alexander M. M. Eggermont, MD, PhD, discusses responses to adjuvant pembrolizumab in patients with different subtypes of stage III melanoma.

Michael J. Morris, MD, discusses the ​design of the phase 3 CONDOR trial in men with biochemically recurrent prostate cancer.

Nancy U. Lin, MD, discusses the development of systemic therapies for the treatment of patients with metastatic HER2-positive breast cancer and brain metastases.

Paolo Ghia, MD, PhD, discusses the efficacy and safety of acalabrutinib in the phase 3 ASCEND trial in relapsed/refractory chronic lymphocytic leukemia.

Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.

Lori A. Leslie, MD, discusses the benefits with zanubrutinib (Brukinsa) in the treatment of patients with mantle cell lymphoma.

Katja Weisel, MD, discusses the interim analysis of the phase 2 GMMG-Concept trial with isatuximab-irfc in combination with carfilzomib, lenalidomide, and dexamethasone in high-risk patients with newly diagnosed multiple myeloma.

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.

Matthew S. Davids, MD, MMSc, discusses updated findings from a phase 1/1b study which examined the combination of ibrutinib (Imbruvica) and umbralisib in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma.

Jesus G. Berdeja, MD, discusses the dosing of the investigational CAR T-cell product JNJ-4528 in patients with ​relapsed/refractory multiple myeloma.

​Neal D. Shore, MD, FACS, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses second-line treatment options in hepatocellular carcinoma.

Eric Jonasch, MD, discusses the safety profile of the investigational oral hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Scott Kopetz, MD, PhD, FACP, discusses the rationale for the phase 3 BEACON CRC trial in BRAF V600E-mutant metastatic colorectal cancer.

Chetasi Talati, MD, discusses the design of a chart review study with venetoclax and hypomethylating agents in older patients with newly-diagnosed acute myeloid leukemia.

Thomas A. Hope, MD, discusses the positive findings from a phase 3 imaging study, which utilized 68Ga-PSMA-11 PET in the detection of pelvic nodal metastasis in men with intermediate- or high-risk prostate cancer.

Neal D. Shore, discusses the potential utility of relugolix in patients with advanced prostate cancer.

Ritu Salani, MD, MBA, discusses the current state of biomarker testing in cervical cancer.

Christian U. Blank, MD, PhD, discusses adjuvant versus neoadjuvant approaches in macroscopic stage III melanoma.